shire_image_4

NICE turns down Shire’s pancreatic cancer treatment

pharmafile | April 4, 2017 | News story | Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire 

NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment of metastatic pancreatic cancer that has progressed following gemcitabine-based therapy.

The committee came to the decision based on evidence for the use of the drug in combination with 5-fluorouracil (5-FU), a chemotherapy drug, and leucovorin (LV), which improves the effect of 5-FU. Onivyde consists of fat particles to which the anticancer treatment irinotecan has been added, meaning that the drug can travel into a tumour and slowly inhibit its ability to grow, eventually leading to its death.

The combination of Onivyde, 5-FU and LV has shown to generate an overall median survival rate of 6.1 months compared to the 4.2 months provided by 5-FU and LV alone. However, NICE judged that, when compared to the clinical standard of oxaliplatin plus 5-FU and LV, Onivyde did not present any significant benefits. With this comparison in mind, the committee could not deem the treatment a cost-effective use of NHS resources, despite the uncertainty of the evidence available.

Advertisement

Pancreatic cancer is an aggressive form of the disease affecting up to 10,000 new patients a year in the UK, with only 3% of sufferers surviving for more than five years. This decision leaves patients with limited options to treat the illness; today, survival rates are often less than six months.

Matt Fellows

Related Content

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

money-2180330_960_720

Anocca secures £32m to advance pancreatic cancer trial

Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development …

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content